Vera Therapeutics Inc (VERA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Vera Therapeutics Inc (VERA) has a cash flow conversion efficiency ratio of -0.116x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-69.99 Million) by net assets ($604.52 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See how many days can Vera Therapeutics Inc fund operations to measure how many days the company can operate on defensive assets alone.
Vera Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how Vera Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Vera Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Vera Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Freshpet Inc
NASDAQ:FRPT
|
0.032x |
|
TAG IMMOBILIEN ADR 1/2
F:TEG0
|
0.040x |
|
Beijing Worldia Diamond Tools Co Ltd
SHG:688028
|
0.028x |
|
Zhuzhou CRRC Times Electric Co. Ltd
F:ZTX
|
0.069x |
|
Kitron ASA
OL:KIT
|
0.014x |
|
Hubei Wanrun New Energy Technology Co. Ltd. A
SHG:688275
|
N/A |
|
Rogers Corporation
NYSE:ROG
|
0.005x |
|
Unibel S.A
PA:UNBL
|
0.077x |
Annual Cash Flow Conversion Efficiency for Vera Therapeutics Inc (2019–2025)
The table below shows the annual cash flow conversion efficiency of Vera Therapeutics Inc from 2019 to 2025. For the full company profile with market capitalisation and key ratios, see Vera Therapeutics Inc (VERA) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $604.52 Million | $-241.10 Million | -0.399x | -70.92% |
| 2024-12-31 | $577.15 Million | $-134.68 Million | -0.233x | +74.26% |
| 2023-12-31 | $101.69 Million | $-92.18 Million | -0.907x | -3.14% |
| 2022-12-31 | $76.91 Million | $-67.60 Million | -0.879x | -158.00% |
| 2021-12-31 | $69.59 Million | $-23.71 Million | -0.341x | -187.44% |
| 2020-12-31 | $-89.35 Million | $-34.81 Million | 0.390x | +38.39% |
| 2019-12-31 | $-36.55 Million | $-10.29 Million | 0.282x | -- |
About Vera Therapeutics Inc
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with immunological diseases. The company offers atacicept, a fully humanized TACI-Fc fusion protein that binds B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL), which is self-administered at home as a subcutaneous in… Read more